Select Bibliography

Filter by any of these (after searching):

Lai, R.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 7 items

Use of gene expression profiling to identify responsive patients treated with carboplatin (Carb), paclitaxel (Pac), and everolimus as first-line treatment for cancer of unknown primary (CUP): NCCTG N0871 (Alliance)

Goetz, M. , Foster, N. , Meyers, J. , Steen, P. , Visscher, D. ... - ASCO - J Clin Oncol - 2013

Abstract - Primary - Primary - Experimental - NCCTG-N0871

Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study

Hsi, E. D. , Said, J. , Johnson, J. L. , Jung, S. , Lai, R. , Jones, D. ... - ASH - Blood - 2008

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-50103

Ki67 and PIM1 expression in aggressively treated mantle cell lymphoma (MCL): A Cancer and Leukemia Group B (CALGB) 59909 correlative science study

Hsi, E. , Jung, S. , Lai, R. , Johnson, J. , Cook, J. , Jones, D. ... - ASCO - J Clin Oncol - 2008

Abstract - Secondary-not-in-original - Primary - Lymphoma - CALGB-59909

Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials

Reiman, T. , Lai, R. , Veillard, A. S. , Paris, E. , Soria, J. C. ... - - Ann Oncol - 2012

Manuscript - Secondary-not-in-original - Comprehensive - Respiratory - CALGB-9633

Prognostic value of Class III B-Tubulin (TUBB3) in operable non-small cell lung cancer (NSCLC) and predictive value for adjuvant cisplatin based chemotherapy (CT): A validation study on 3 randomized trials

Reiman, T. , Seve, P. , Vataire, A. , Dunant, A. , Rosell, R. ... - ASCO - J Clin Oncol - 2008

Abstract - Secondary-not-in-original - Comprehensive - Respiratory - CALGB-150802

A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype

Wilson, W. H. , Jung, S. H. , Porcu, P. , Hurd, D. , Johnson, J. ... - - Haematologica - 2012

Manuscript - Primary - Primary - Lymphoma - CALGB-50103

Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (Alliance)

Yoon, H. H. , Foster, N. R. , Meyers, J. P. , Steen, P. D. ... - - Ann Oncol - 2016

Manuscript - Primary - Primary - Experimental - NCCTG-N0871